

Applicant : BAKHUTASHVILI, Vladimir
U.S. Serial No.: 09/928,178
Filed : August 9, 2001
Date : February 19, 2002
Page : 2

REMARKS

Applicant intends to claim priority of U.S. Serial No. 60/224,112, filed August 9, 2000 as evidenced in applicant's Declaration and Power of Attorney attached hereto as **Exhibit A**. Accordingly, applicant maintains that there is no issue of new matters and respectfully requests the entry of this Amendment.

Applicant attaches hereto a mark-up copy of the first page of the specification as **Exhibit B**. Applicant further attached hereto a clean copy of the first page of the specification as **Exhibit C**.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai Kit Chan

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant
141-07 20th Ave., Suite 604
Whitestone, New York 11357
Tel: (718) 357-8836
Fax: (718) 357-8552

I hereby certify that this paper is being deposited this date with the U.S. Postal Service as first class mail addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Albert Wai Kit Chan 2/19/02
Albert Wai-Kit Chan Date
Reg. No. 36,479



CO. OF PAPERS
ORIGINALLY FILED

Dkt. # 627A

TECH CENTER 1600/2900

MAR 18 2002

RECEIVED

AMNIOTIC APOPTOSIS MODULATING SUBSTANCES

5 This application claims the benefit of United States
patent application Serial No. 60/224,112, filed on
August 9, 2000, the content of which is incorporated
here into this application.

10 Throughout this application, references are made to
various publications. Disclosures of these
publications in their entirety are hereby
incorporated by reference into this application to
more fully describe the state of the art to which
this invention pertains.

15

FIELD OF THE INVENTION

20 The invention(s) is directed to method(s) of
obtaining compounds from human amniotic tissue
and/or by synthesizing these compounds by chemical
and genetic engineering methods known in the art
that modulate apoptosis in animals, including
humans, their preparation, their applications in
human conditions for the treatment of all disease
25 conditions and other conditions in which apoptosis
occurs and in laboratory tests for diagnostic
studies and other potential uses.

BACKGROUND OF THE INVENTION

30

APOPTOSIS

Apoptosis is a mode of cell death that occurs under
normal physiological conditions. It is an active
genetically controlled process, which removes
35 unnecessary and damaged cells. Apoptosis enables
living organisms to control cell numbers in tissues
and to eliminate individual cells that jeopardize
the living organism. It takes place in developing
embryos and in adult organisms during physiological
40 tissue turnover and in most pathological processes.



COPY OF PAPERS
ORIGINALLY FILED

Dkt. # 627A

TECH CENTER 1600/2900

MAR 18 2002

RECEIVED

AMNIOTIC APOPTOSIS MODULATING SUBSTANCES

5 This application claims the benefit of United States
patent application Serial No. 60/224,112, filed on
August 9, 2000, the content of which is incorporated
here into this application.

10 Throughout this application, references are made to
various publications. Disclosures of these
publications in their entireties are hereby
incorporated by reference into this application to
more fully describe the state of the art to which
this invention pertains.

15

FIELD OF THE INVENTION

The invention(s) is directed to method(s) of
obtaining compounds from human amniotic tissue
20 and/or by synthesizing these compounds by chemical
and genetic engineering methods known in the art
that modulate apoptosis in animals, including
humans, their preparation, their applications in
human conditions for the treatment of all disease
25 conditions and other conditions in which apoptosis
occurs and in laboratory tests for diagnostic
studies and other potential uses.

BACKGROUND OF THE INVENTION

30

APOPTOSIS

Apoptosis is a mode of cell death that occurs under
normal physiological conditions. It is an active
genetically controlled process, which removes
35 unnecessary and damaged cells. Apoptosis enables
living organisms to control cell numbers in tissues
and to eliminate individual cells that jeopardize
the living organism. It takes place in developing
embryos and in adult organisms during physiological
40 tissue turnover and in most pathological processes.